Pandion Therapeutics Revenue and Competitors

Boston, MA USA

Location

$138M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pandion Therapeutics's estimated annual revenue is currently $9.5M per year.(i)
  • 0
  • Pandion Therapeutics's total funding is $138M.

Employee Data

    00

Pandion Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Pandion Therapeutics?

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandionᅢᄁ¬ツᆲ¬トᄁs approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

keywords:N/A

$138M

Total Funding

N/A

Number of Employees

$9.5M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pandion Therapeutics News

2022-04-13 - Seismic Therapeutic Appoints Eric Larson as Senior Vice President ...

Prior to joining Seismic, Eric was Vice President of Finance at Pandion Therapeutics where he built the finance and accounting...

2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a global ...

... Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; grants from AbbVie, MSD,...

2022-03-22 - Venture Philanthropy Catalyzes T1D Therapeutic Development

“Ultimately, our investment in Pandion Therapeutics helped catalyze their pancreas program, which started off with a relatively small investment...

2020-04-01 - Pandion Therapeutics Closes $80M Series B Financing

Pandion Therapeutics, Inc., a Cambridge, MA-based clinical-stage, biotechnology company developing modular protein therapeutics for autoimmune disease, closed an $80m Series B financing. The round was led by Access Biotechnology and Boxer Capital with participation from RA Capital and OrbiMed a ...

2018-01-18 - Pandion Therapeutics Raises $58M Series A Financing

Pandion Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, completed a $58m Series A financing. The round was co-led by Polaris Partners, Versant Ventures and Roche Venture Fund, with participatio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$64.9M0N/A$751.3M
#2
$12.9M0N/A$163M
#3
$9.8M0N/A$39M
#4
$4.8M0N/AN/A
#5
$33.3M0N/A$15M